Review Article| Volume 29, ISSUE 3, P503-509, September 2009

Drug-of-Abuse Testing at the Point of Care


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Watson I.
        Clinical drug testing at the point of care.
        2nd edition. AACC Press, Washington (DC)2004
        • Wu A.H.
        • McKay C.
        • Broussard L.A.
        • et al.
        National academy of clinical biochemistry laboratory medicine practice guidelines: recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department.
        Clin Chem. 2003; 49: 357-379
        • Heit H.A.
        • Gourlay D.L.
        Urine drug testing in pain medicine.
        J Pain Symptom Manage. 2004; 27: 260-267
        • Trescot A.M.
        • Boswell M.V.
        • Atluri S.L.
        • et al.
        Opioid guidelines in the management of chronic non-cancer pain.
        Pain Physician. 2006; 9: 1-39
        • Lewandrowski K.
        • Flood J.
        • Finn C.
        • et al.
        Implementation of point-of-care rapid urine testing for drugs of abuse in the emergency department of an academic medical center: impact on test utilization and ED length of stay.
        Am J Clin Pathol. 2008; 129: 796-801
        • George S.
        • Braithwaite R.A.
        Use of on-site testing for drugs of abuse.
        Clin Chem. 2002; 48: 1639-1646
        • Hicks J.M.
        • Haeckel R.
        • Price C.P.
        • et al.
        Recommendations and opinions for the use of point-of-care testing for hospitals and primary care: summary of a 1999 symposium.
        Clin Chim Acta. 2001; 303: 1-17
        • Watson I.
        • Bertholf R.
        • Hammett-Stabler C.
        • et al.
        Drugs and ethanol.
        National Academy of Clinical Biochemistry, Washington (DC)2006
        • Leino A.
        • Saarimies J.
        • Gronholm M.
        • et al.
        Comparison of eight commercial on-site screening devices for drugs-of-abuse testing.
        Scand J Clin Lab Invest. 2001; 61: 325-331
        • Pil K.
        • Verstraete A.
        Current developments in drug testing in oral fluid.
        Ther Drug Monit. 2008; 30: 196-202
        • Bendtsen P.
        • Hultberg J.
        • Carlsson M.
        • et al.
        Monitoring ethanol exposure in a clinical setting by analysis of blood, breath, saliva, and urine.
        Alcohol Clin Exp Res. 1999; 23: 1446-1451
        • Haller C.A.
        • Stone J.
        • Burke V.
        • et al.
        Comparison of an automated and point-of-care immunoassay to GC-MS for urine oxycodone testing in the clinical laboratory.
        J Anal Toxicol. 2006; 30: 106-111
        • Leino A.
        • Loo B.M.
        Comparison of three commercial tests for buprenorphine screening in urine.
        Ann Clin Biochem. 2007; 44: 563-565
        • Phillips J.E.
        • Bogema S.
        • Fu P.
        • et al.
        Signify ER Drug Screen Test evaluation: comparison to Triage Drug of Abuse Panel plus tricyclic antidepressants.
        Clin Chim Acta. 2003; 328: 31-38
        • Schwartz J.G.
        • Hurd I.L.
        • Carnahan J.J.
        Determination of tricyclic antidepressants for ED analysis.
        Am J Emerg Med. 1994; 12: 513-516
        • Yang J.M.
        • Lewandrowski K.B.
        Urine drugs of abuse testing at the point-of-care: clinical interpretation and programmatic considerations with specific reference to the Syva Rapid Test (SRT).
        Clin Chim Acta. 2001; 307: 27-32
        • de la Torre R.
        • Domingo-Salvany A.
        • Badia R.
        • et al.
        Clinical evaluation of the Triage analytic device for drugs-of-abuse testing.
        Clin Chem. 1996; 42: 1433-1438
        • Mastrovitch T.A.
        • Bithoney W.G.
        • DeBari V.A.
        • et al.
        Point-of-care testing for drugs of abuse in an urban emergency department.
        Ann Clin Lab Sci. 2002; 32: 383-386
        • Poklis A.
        • Poklis J.L.
        • Tarnai L.D.
        • et al.
        Evaluation of the Triage PPY on-site testing device for the detection of dextropropoxyphene in urine.
        J Anal Toxicol. 2004; 28: 485-488
        • Taylor E.H.
        • Pizzo P.
        Evaluation of the DrugCheck 9 on-site immunoassay test cup according to a standard method validation protocol.
        J Anal Toxicol. 2004; 28: 190-197
        • Moody D.E.
        • Fang W.B.
        • Andrenyak D.M.
        • et al.
        A comparative evaluation of the instant-view 5-panel test card with OnTrak TesTcup Pro 5: comparison with gas chromatography-mass spectrometry.
        J Anal Toxicol. 2006; 30: 50-56
        • Tomaszewski C.
        • Runge J.
        • Gibbs M.
        • et al.
        Evaluation of a rapid bedside toxicology screen in patients suspected of drug toxicity.
        J Emerg Med. 2005; 28: 389-394
        • Wu A.H.
        • Wong S.S.
        • Johnson K.G.
        • et al.
        Evaluation of the triage system for emergency drugs-of-abuse testing in urine.
        J Anal Toxicol. 1993; 17: 241-245
        • Taylor E.H.
        • Oertli E.H.
        • Wolfgang J.W.
        • et al.
        Accuracy of five on-site immunoassay drugs-of-abuse testing devices.
        J Anal Toxicol. 1999; 23: 119-124